is expected to arise 6 at temperatures of several hundred kelvin.
The second obstacle is that the physics of the Hubbard model is highly dependent on the density of fermions in the lattice. If there is exactly one particle per lattice site, the model offers no surprises -the system has magnetic order and is an insulator whose properties are well known in all spatial dimensions (Fig. 1b) . But if the density of fermions in the system is reduced, in a process called doping, the magnetic order is lost and the model enters unknown territory (Fig. 1c) . Unfortunately, ultracold atomic systems are usually confined in such a way that their density becomes highly spatially inhomogeneous, causing these different physical properties to be scrambled. Despite intensive efforts and partial solutions to these two problems, it has been unclear how the physics of the 'doped' Hubbard model could be observed in a realistic experiment.
Mazurenko and colleagues' study provides a key step in this direction. The authors use a device called a fermionic microscope, which allows fermions to be accessed and controlled at the level of individual lattice sites. The experimental set-up consists of two parts: a system of particles whose properties are measured and a surrounding sea of particles that acts as a coolant. The authors' system attains temperatures that are substantially lower (at about 12 nK) than observed in previous experiments 2 . These temperatures allow them to achieve magnetic order for their whole system -a first for these types of experiment.
Even more importantly, Mazurenko et al. can precisely control the density of particles in their system. They show that the magnetic order disappears if the system is doped, in agreement with theoretical expectations of the Hubbard model. Although the authors do not observe new physics, their work is a spectacular advance that puts ultracold-atom experiments firmly in a position to crack the physics of the 2D Hubbard model -in regimes for which the simulations performed in classical computers are becoming almost intractable.
Clearly, Mazurenko and colleagues' experiment will stimulate researchers to use quantum microscopes or other techniques to push the analysis of the Hubbard model further. There is therefore little doubt that rapid progress will be made, and that the doped regime will be explored in a controlled way. The Hubbard model could very well reveal all of its secrets soon, opening the door to an understanding of the materials of the twentyfirst century. ■ 13-125 (1996) .
Thierry Giamarchi is in the Department

BLOOD
Education for stem cells
Haematopoietic stem cells give rise to all lineages of blood cell, and their production in vitro has been a long-sought goal of stem-cell biology. Two groups now achieve this feat through different means. See Articles p.432 & p.439
T he entire mammalian blood system can be restored from a single haematopoietic stem cell (HSC). These selfrenewing cells reside in the bone marrow, where their proliferation and differentiation are tightly regulated to ensure a continued, lifetime supply of blood cells. The high regenerative capacity of HSCs makes them central to life-saving bone-marrow transplants, but also makes them prone to acquiring leukaemia-initiating genetic mutations. The ability to manufacture HSCs in the laboratory therefore holds enormous promise for cell therapy, drug screening and studies of leukaemia development. Two studies 1,2 in this issue outline protocols to achieve just that.
In the embryo, the first HSCs are thought to develop from specialized 'haemogenic' endothelial cells that line the walls of a blood vessel called the dorsal aorta 3, 4 . The precise molecular mechanisms behind this intriguing conversion remain to be defined, but are widely thought 5 to be important for successful in vitro generation of HSCs. The current studies took this supposition as the basis for the development of their protocols.
In the first study, Sugimura et al.
1
(page 432) started with human pluripotent stem cells (PSCs), which can give rise to any cell type in the body. The authors adapted a previous method 6 to derive haemogenic endothelial cells from human PSCs. They then identified a subset of seven transcription factors that could induce the haemogenic endothelial cells to become immature HSCs.
In the second study, Lis et al. 2 (page 439) directly converted adult mouse endothelial cells to immature HSCs through transient expression of a panel of four transcription-factor genes, including two, Runx1 and Spi1, that were also used by Sugimura and colleagues. The group's strategy opens up the exciting prospect that HSCs could eventually be directly induced from a person's own tissues.
The development of HSCs has been likened to progression from a maternity ward to a finishing school 7 , with the former being where HSCs are born, and the latter where they mature in response to external signals. This analogy seems fitting for the current papers (Fig. 1) . In both cases, programming by transcription factors was required for HSC birth, and extracellular cues were essential for subsequent maturation.
Sugimura et al. provided 'finishing school' cues by transplanting their HSCs into the bone marrow of adult mice. By contrast, Lis and colleagues grew their cells on a layer of endothelial cells taken from the umbilical cord, which released as-yet-undefined factors that support HSC development, before transplantation into mice. HSCs generated by both protocols could engraft when transplanted into recipients, giving rise to all major blood lineages, and the cells of these animals could engraft in a second recipient -a major step forward compared with previous methods.
The dorsal aorta is believed to act as both a maternity ward and a finishing school for HSCs during normal embryonic development 8 . The layer of endothelial cells used by Lis et al. captures some aspects of this native setting. By contrast, in injecting their cells directly into adult-mouse bone marrow to achieve HSC maturation, Sugimura et al. exposed the cells to signals from the niche in which adult HSCs normally reside. The finishing-school site for Sugimura and colleagues' cells might be the perivascular HSC niche -a region close to blood vessels that is partly made up of endothelial cells. There is accumulating evidence 9 that this niche is involved in the maintenance of adult HSCs. It is therefore plausible that there is more flexibility than previously thought in the type of environment that can support HSC maturation, and that one of the main requirements is an endo thelial wall.
When asked why they should be given public money, developmental biologists have long argued that a better understanding of normal developmental processes will be crucial to the generation of authentic cell types for cell-based therapies and drug screening. The current papers provide excellent examples of this, because their protocols rely on features from embryonic mechanisms. Both studies used endothelial cells as a starting material, in analogy to HSC development in the embryo, and their transcription-factor cocktails included factors, such as RUNX1 and SPI1, that regulate [10] [11] [12] the birth of the first HSCs during embryonic development in vivo.
Despite the excitement that the current papers will generate, there are some notable limitations. For instance, only Lis and colleagues addressed the potential of the programmed HSCs to become cancerous, finding no evidence of leukaemia for up to 20 weeks after engraftment. Longer follow-up will be required -especially for the human cells produced by Sugimura and co-workers.
Future investigations are also likely to focus on how the transcription-factor cocktail is introduced. The current studies used genetic vectors derived from retroviruses that integrate into random sites in the hostcell genome. Expression of the transcription factors is then driven by a drug called doxycycline that can be administered as needed. 'Cleaner' genome-engineering strategies (such as CRISPR-Cas9 technology) that can direct the insertion of sequences into specific sites in the genome are advancing rapidly. These techniques could eliminate concerns that retroviral integration might activate cancercausing genes 13 , or that expression of the transcription factors might not be completely extinguished under inducible, doxycyclinebased systems. The latter is a worry because many of the transcription factors used in the current studies have also been implicated in the initiation of leukaemia.
Another caveat is that only a small minority of cells from the engineered populations produced progeny that could be detected in the bloodstream after a few months. Although this was sufficient to repopulate the blood, further studies will be required to fully define the molecular make-up of HSCs produced in vitro. This is particularly pressing because both studies suggest that, although the programmed cells are similar to HSCs, they are not identical.
HSCs are defined by their ability to engraft and give rise to all blood-cell lineages over many months. This is arguably the most stringent assay of any adult stem cell. Cells fulfilling these criteria have now been produced in two ways -a fact that not only opens up exciting opportunities in the haematopoiesis field, but also represents a milestone for the wider stem-cell community. Although further studies are needed, the long journey to translate the promise of stem-cell research into direct patient benefit may just have become a little shorter. , non-small-cell lung tumours were surgically removed from individuals, and samples were isolated from various regions of the tumour (indicated by the numbers 1-4). Using these samples, Jamal-Hanjani et al.
2 sequenced protein-coding genomic regions, and identified DNA changes (shown as X symbols) that arose in these areas of the tumour. By analysing the patterns of DNA changes, the authors could determine the relationship between mutations. For example, early mutations are likely to be present in all tumour cells (clonal alterations), whereas later mutations occur in only some cells (subclonal alterations). The authors created a phylogenetic tree showing how an individual's tumour evolved. Abbosh et al.
1 used the genetic profiles obtained by Jamal-Hanjani et al. to design a liquid-biopsy blood test for circulating tumour DNA (ctDNA) that could be used to spot the specific genetic hallmarks of cancer relapse appearing in an individual. This personalized testing approach identified signs of tumour recurrence a median of 70 days before relapse was identified through imaging scans. Such recurrence is often seen at different locations from the primary site of tumour formation.
MEDICAL RESEARCH
Personalized test tracks cancer relapse
Genomic analysis of lung-tumour evolution has been used to create personalized blood tests that enable successful clinical monitoring for early signs of cancer relapse -a promising step on the road to precision medicine. See Article p.446 In their experiments, Abbosh and colleagues observed a relationship between their ability to detect ctDNA and the presence of cell necrosis, which is frequently found in some forms of non-small-cell lung cancer. Current advances in the sensitivity and accuracy of liquid biopsy are leading to clinical applications 4, 5 . Abbosh et al. now offer a further advance in ctDNA analysis by testing whether liquid biopsies can be used to monitor the evolution of a cancer at an early stage of disease, and to identify relapse.
The clinical study reported in the current papers is called TRACERx, and is designed to study how non-small-cell lung cancers change over time. The authors began with a cohort of 100 individuals who underwent surgery to remove their tumours. However, efforts to remove all tumour cells are not always successful. Moreover, residual malignant cells might persist after surgery if a few tumour cells have already migrated to other locations in the body. If the patient relapses, additional treatment options such as chemotherapy can be considered.
The authors set out to track the evolution of individual tumours by testing ctDNA from blood samples obtained at different time points. However, the sensitivity of liquid biopsies has been a major challenge because tumour DNA can represent less than 1% of the DNA present in a blood-plasma sample 3 . To devise highly sensitive tests that can identify such a genetic 'needle in a haystack' , Abbosh et al. used information obtained in JamalHanjani and colleagues' analysis of surgically removed lung tumours. Jamal-Hanjani et al. sequenced the entire protein-coding region of the genome in several parts of these excised tumours and sequenced healthy tissue for comparison, to identify DNA changes, known as single nucleotide variants (SNVs), present specifically in the tumour.
The SNV profiles associated with different
